Table 5.
The effects of B. lactis on pediatric allergy.
| Parameters | One-month follow-up | P value | Three-month follow-up | P value | ||
|---|---|---|---|---|---|---|
| BG | CG | BG | CG | |||
| Allergy symptoms | ||||||
| Rash, grades | 1.51 ± 1.13 | 2.56 ± 1.67 | <0.001 | 1.46 ± 1.29 | 2.59 ± 1.85 | <0.01 |
| Eczema, scores | 11.70 ± 9.36 | 32.41 ± 14.61 | <0.001 | 11.59 ± 10.88 | 32.52 ± 15.99 | <0.01 |
| Abdominal cramps/pain, scores | 8.11 ± 6.73 | 22.16 ± 8.41 | <0.001 | 6.03 ± 5.26 | 22.09 ± 11.44 | <0.01 |
| Vomiting, grades | 1.05 ± 0.97 | 2.23 ± 1.65 | <0.001 | 1.16 ± 1.08 | 2.31 ± 1.89 | <0.01 |
| IgE (μg/ml) | 2.27 ± 1.94 | 5.82 ± 3.90 | <0.001 | 1.53 ± 1.38 | 5.96 ± 4.97 | <0.01 |
Note. BG, the patients received B. lactis treatment; CG, the patients received the solution without B. lactis treatment; TSS, total allergy symptom score. n = 126 and 124 for BG and CG groups, respectively, after one-month follow-up. n = 123 and 120 for BG and CG, respectively, after three-month follow-up. All data were presented as mean ± SD (standard derivation). The statistical difference was significant if P < 0.05 when compared with the control group.